Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL - Wikidata - wikimedia - TriplyDB

Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL

Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL

http://www.wikidata.org/entity/Q36209190

about

Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus Current issues and future directions of oncolytic adenoviruses.Tumor-targeted delivery of biologically active TRAIL protein.Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities Inducible gene expression in tumors colonized by modified oncolytic vaccinia virus strains Increasing the efficacy of oncolytic adenovirus vectors Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer.Generation of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy.Synthetic riboswitches for external regulation of genes transferred by replication-deficient and oncolytic adenoviruses.Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded.Armed replicating adenoviruses for cancer virotherapy.Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents Cytokine determinants of viral tropism."Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment.Oncolytic (replication-competent) adenoviruses as anticancer agents.Evolution of oncolytic viruses: novel strategies for cancer treatment.Oncolytic Immunotherapy for Treatment of Cancer.Oncolytic virus therapy for cancer.Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro.Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity Role of Gene Therapy in Pancreatic Cancer-A Review.

P2860

Q33622711-3084DEC4-F392-41A7-8DB4-4FD85FB66BCF Q33690982-ECD72629-09C9-4FA0-93D7-C49BE2D61002 Q33730705-A168A5AD-A9DF-47F6-96BB-F46C5E531530 Q33809123-3742E44A-17EC-468A-B923-191D33A4AF31 Q33906116-1A0D51EA-16DB-4E5F-87D6-3409F6F832FE Q34139691-C6F5CCB0-7AD6-463B-A77E-7131487525CB Q34262005-59D0FDA1-5039-4395-A7B1-EC2F175BFA3E Q35261325-B2E3A385-276C-46C6-B0AB-5AC5C781F673 Q35563005-0D51F89B-4A16-460D-8EEF-A42A280163A4 Q36306398-B90D634A-ABFA-485D-A568-7B732E24B532 Q36422224-8E726CCA-2A8F-4A6B-8E0D-7C1C23C348FC Q37191007-486B0F35-5247-4BCF-8AE7-44BFBD5AB0AE Q37386616-C5D3700D-CC1B-4C2A-A350-1A108355A82B Q37442235-19C32538-9684-4CB5-A585-4C71405BA1E7 Q37583568-9FF8EF29-FFF3-497E-B79A-2493DC2FB7AC Q37622288-62402B2F-BB60-4E9E-83D0-69D0ED5CC7FB Q37687415-9C5AB942-D72F-436B-ABAA-D7A35903F345 Q38159802-71C85BED-D106-4E8A-B489-DE726A860C05 Q38848223-5671B157-0516-445C-9308-545B64B0B16F Q38924529-5D624D4E-2EC7-4255-AB95-191297BF3110 Q39673855-5D0BAA2B-227F-46E6-A27D-8FC20CAD9D58 Q41770092-01E5C607-12CA-4509-9648-EBBD0EFABAB7 Q52610258-C9D44472-D1AC-4758-ACF8-C8CD691CA59B

P2860

Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL

http://www.wikidata.org/entity/Q36209190

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Anticancer activity of oncolyt ...... controlled expression of TRAIL

@ast

Anticancer activity of oncolyt ...... controlled expression of TRAIL

@en

type

label

Anticancer activity of oncolyt ...... controlled expression of TRAIL

@ast

Anticancer activity of oncolyt ...... controlled expression of TRAIL

@en

prefLabel

Anticancer activity of oncolyt ...... controlled expression of TRAIL

@ast

Anticancer activity of oncolyt ...... controlled expression of TRAIL

@en

P1433

Q36209190-CDCEF6BE-BDC6-43F2-8D66-B4226FC83BF9

P1476

Q36209190-0C23C6AA-938A-420E-998C-F9E843AD7E02

P2093

Q36209190-46DC4C32-1A10-416E-8832-94C500E893E1

Q36209190-89CAB320-D12E-4068-BFD5-97773BAA6A93

Q36209190-D4DA678A-6F91-426F-B825-C83D3E56CB71

Q36209190-D948E1B0-7B0B-4ACC-8844-60274900FBF3

P2860

Q36209190-057E5992-5273-4354-96EE-5FD549C37FB2

Q36209190-061FD912-324A-48C6-8FA7-EA1BCCFA6CD4

Q36209190-0D60F163-A5F5-4558-9D3A-06413F615A4A

Q36209190-146A4BF0-FD74-47D6-AD04-DBE0962AD630

Q36209190-293ECAF4-6F1C-4DCC-8FDD-DECB492AE65B

Q36209190-2FD7567D-E9C3-4309-9E68-3502E6A1F7B3

Q36209190-33409BFD-0EFE-4372-9D6A-38F2CC98370B

Q36209190-39A8D60C-EE96-4DC0-9137-0C58ECFB973B

Q36209190-43C11083-55B0-4B48-B0AD-0ECE8EB94FE9

Q36209190-4C2DC6A3-69AB-424A-BCD2-D8C65870BF55

P2888

Q36209190-FED05002-D63F-4779-B3F7-AA68A60A0000

P304

Q36209190-697166E3-08D2-4D65-B329-D4B0B44C0F5B

P31

Q36209190-04737068-C280-4CCE-AE8F-86BED3A97B54

P356

Q36209190-B8304B02-1F90-4799-B757-EB65C6E7CCC8

P433

Q36209190-6702DF7F-4022-4554-B4AB-A5BA3A781F44

P478

Q36209190-299C8587-84F4-4BAC-99AC-233B8FC37DB0

P577

Q36209190-99DFE99D-DCF8-4346-97B7-DF966F5A59DB

P5875

Q36209190-D7CE765B-6FEC-45AA-A339-B3592C08BD4C

P6179

Q36209190-E1E0EB9B-E116-4CFD-95BF-FB01FBD7F5F0

P698

Q36209190-61A5C4E6-F9F8-4518-AD9F-7C33C4C05CA5

P921

Q36209190-33EFB055-FD12-4668-9441-BBDF4DFDD928

Q36209190-6DF42866-0C2F-4E7A-BFFF-BF0BDAF291EA

Q36209190-F548DDAC-1F4F-4BC0-B298-699DB26B6927

P932

Q36209190-A9FC6DBC-F657-4648-911E-EC6D4386AF9A

P356

P1433

Cancer Gene Therapy

P1476

Anticancer activity of oncolyt ...... controlled expression of TRAIL

@en

P2093

E V Shashkova

http://www.w3.org/2001/XMLSchema#string

K Doronin

http://www.w3.org/2001/XMLSchema#string

M N Kuppuswamy

http://www.w3.org/2001/XMLSchema#string

W S M Wold

http://www.w3.org/2001/XMLSchema#string

P2860

Identification and characterization of a new member of the TNF family that induces apoptosis

The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors

Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein

Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins.

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.

Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis.

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models.

Genetic identification of adenovirus type 5 genes that influence viral spread.

P2888

P304

61-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.CGT.7701107

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2007-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5854969

http://www.w3.org/2001/XMLSchema#string

P6179

1027825695

http://www.w3.org/2001/XMLSchema#string

P698

17992200

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

3433948

http://www.w3.org/2001/XMLSchema#string